[14] Anti-CD40 antibodies prepared from patients with recurrent FSGS, indeed, do not recognize human CD40, yet they are able to produce podocyte damage in vitro and in vivo [14]. This evidence concerns the gene CD40 and focal segmental glomerulosclerosis.